Logo image of BOLD

BOUNDLESS BIO INC (BOLD) Stock Fundamental Analysis

NASDAQ:BOLD - Nasdaq - US10170A1007 - Common Stock - Currency: USD

1.96  -0.04 (-2%)

After market: 2 +0.04 (+2.04%)

Fundamental Rating

2

Overall BOLD gets a fundamental rating of 2 out of 10. We evaluated BOLD against 571 industry peers in the Biotechnology industry. BOLD has a great financial health rating, but its profitability evaluates not so good. BOLD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BOLD had negative earnings in the past year.
In the past year BOLD has reported a negative cash flow from operations.
BOLD Yearly Net Income VS EBIT VS OCF VS FCFBOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of BOLD (-34.87%) is better than 62.21% of its industry peers.
BOLD's Return On Equity of -36.99% is fine compared to the rest of the industry. BOLD outperforms 73.26% of its industry peers.
Industry RankSector Rank
ROA -34.87%
ROE -36.99%
ROIC N/A
ROA(3y)-39.99%
ROA(5y)N/A
ROE(3y)-44.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BOLD Yearly ROA, ROE, ROICBOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLD Yearly Profit, Operating, Gross MarginsBOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

BOLD has about the same amout of shares outstanding than it did 1 year ago.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLD Yearly Shares OutstandingBOLD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
BOLD Yearly Total Debt VS Total AssetsBOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.94, we must say that BOLD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BOLD (0.94) is better than 66.67% of its industry peers.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.94
ROIC/WACCN/A
WACCN/A
BOLD Yearly LT Debt VS Equity VS FCFBOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 17.03 indicates that BOLD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.03, BOLD belongs to the top of the industry, outperforming 91.09% of the companies in the same industry.
BOLD has a Quick Ratio of 17.03. This indicates that BOLD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BOLD (17.03) is better than 91.09% of its industry peers.
Industry RankSector Rank
Current Ratio 17.03
Quick Ratio 17.03
BOLD Yearly Current Assets VS Current LiabilitesBOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

BOLD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.70%.
EPS 1Y (TTM)-7.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -18.38% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-200.22%
EPS Next 2Y-23.2%
EPS Next 3Y-18.38%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BOLD Yearly Revenue VS EstimatesBOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026
BOLD Yearly EPS VS EstimatesBOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLD Price Earnings VS Forward Price EarningsBOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLD Per share dataBOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

BOLD's earnings are expected to decrease with -18.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.2%
EPS Next 3Y-18.38%

More info and screens

0

5. Dividend

5.1 Amount

BOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOUNDLESS BIO INC

NASDAQ:BOLD (2/21/2025, 8:04:01 PM)

After market: 2 +0.04 (+2.04%)

1.96

-0.04 (-2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners74.5%
Inst Owner Change-97.51%
Ins Owners3.05%
Ins Owner Change0%
Market Cap43.71M
Analysts82.22
Price Target14.79 (654.59%)
Short Float %1.68%
Short Ratio3.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.29%
Min EPS beat(2)2.94%
Max EPS beat(2)5.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-2.75
EYN/A
EPS(NY)-3.37
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0
BVpS7.4
TBVpS7.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.87%
ROE -36.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.99%
ROA(5y)N/A
ROE(3y)-44.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 225.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.03
Quick Ratio 17.03
Altman-Z 0.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)159.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.24%
EPS Next Y-200.22%
EPS Next 2Y-23.2%
EPS Next 3Y-18.38%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.79%
EBIT Next 3Y-13.57%
EBIT Next 5YN/A
FCF growth 1Y-16.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.33%
OCF growth 3YN/A
OCF growth 5YN/A